Report of satellite workshop on interim-PET in Hodgkin lymphoma: 8th International Symposium on Hodgkin Lymphoma, Cologne, 23 October 2010

Leukemia and Lymphoma

Volumn 52, Issue 4, 2011, Pages 583-586

  Gallamini, Andrea ^a   O'Doherty, Michael ^b  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER RADIOTHERAPY; CANCER STAGING; CONFERENCE PAPER; HODGKIN DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STANDARDIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 79953172604     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.551162     Document Type: Conference Paper

References (18)

1. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37:181-200.
2. Barrington SF, MacKewn JE, Schleyer P, et al. Establishment of a UK wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. Ann Oncol 2010;Sep 2. [Epub ahead ofprint]
3. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET in lymphoma. Leuk Lymphoma 2009;50:1257-1260.
4. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European Centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824-1833.
5. Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma 2009;50:1761-1764.
6. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2004;16:1160-1168. (Pubitemid 41418320)
7. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and pro-gression-free survival in Hodgkin lymphoma. Blood 2006;107: 52-56.
8. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91: 475-481.
9. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006;17:1296-1270.
10. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomogra-phy is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-3752. (Pubitemid 47372616)
11. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeox-yglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009:27:1906-1914.
12. Cerci JJ, Pracchia LF, Linardi CCG, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 2010;51:1337-1343.
13. Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2010 Dec 20. [Epub ahead of print]
14. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006;107: 2678-2687. (Pubitemid 44845624)
15. Hutchings M, Kostakoglu L, Loft A, Coleman M, Specht L. Correlation of FDG-PET results after one cycle and after two cycles of chemotherapy in Hodgkin lymphoma. J Clin Oncol 2010;28(15 Suppl.): Abstract 8061.
16. Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Ann Oncol 2010;21:126-132.
17. Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment ofoutcome. Blood 2007;109:905-909. (Pubitemid 46220633)
18. Markova J, Kobe C, Skopalova M, et al. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol 2009;20:1270-1274.